Metastatic Hormone Sensitive Prostate Cancer Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting metastatic hormone sensitive prostate cancer clinical trials across 19 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Kaohsiung City, Taiwan, Nashville, Tennessee, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Metastatic Hormone Sensitive Prostate Cancer Trials at a Glance

9 actively recruiting trials for metastatic hormone sensitive prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Kaohsiung City, Nashville, and Barcelona. Lead sponsors running metastatic hormone sensitive prostate cancer studies include Bayer, Astellas Pharma Global Development, Inc., and Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD.

Browse metastatic hormone sensitive prostate cancer trials by phase

Treatments under study

About Metastatic Hormone Sensitive Prostate Cancer Clinical Trials

Looking for clinical trials for Metastatic Hormone Sensitive Prostate Cancer? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Hormone Sensitive Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Hormone Sensitive Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Metastatic Hormone Sensitive Prostate Cancer
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD320 enrolled56 locationsNCT07333066
Recruiting
Phase 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer
Novartis Pharmaceuticals150 enrolled67 locationsNCT06991556
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Metastatic Hormone Sensitive Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer600 enrolled1 locationNCT06334120
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled33 locationsNCT07005154
Recruiting

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Bayer1,400 enrolled1 locationNCT07406282
Recruiting
Phase 1Phase 2

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
AdvanCell Pty Limited100 enrolled3 locationsNCT05720130
Recruiting
Phase 1

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.12 enrolled1 locationNCT07339267